The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Antihypertensive Effect of Lisinopril Assessed by 24‐Hour Ambulatory Monitoring: A Double‐Blind, Placebo‐Controlled, Cross‐Over Study
Summary : The antihypertensive effect of the angiotensin-converting enzyme ( ACE ) inhibitor lisinopril administered in a single dose of 20 mg was evaluated by ambulatory blood pressure monitoring ( ABPM ) in a double-blind , placebo-controlled , cross-over study . Twenty-four patients ( 21 men and 3 women , mean age 52 ± 6 years ) with mild to moderate hypertension were included in the study and r and omly assigned to two consecutive treatments with lisinopril 20 mg and placebo , each administered for 4 weeks . On the last day of each treatment , BP was assessed by noninvasive 24-h ABPM . BP was significantly lower  after lisinopril than after placebo in a 24-h period ( mean 24-h systolic BP ( SBP )  with lisinopril 120 ± 7 mm Hg and with placebo 135 ± 9 mm Hg ; mean day SBP with lisinopril 125 ± 3 mm Hg and with placebo 142 ± 5 mm Hg ; mean night SBP with lisinopril 112 ± 4 mm Hg and with placebo 124 ± 6 mm Hg ; mean 24-h diastolic BP ( DBP )  with lisinopril 76 ± 6 mm Hg , and with placebo 87 ± 8 mm Hg ; mean day DBP  with lisinopril 80 ± 3 mm Hg and with placebo 93 ± 4 mm Hg ; mean night DBP  with lisinopril 69 ± 2 mm Hg and with placebo 79 ± 5 mm Hg , p < 0.001 ) . Mean 24-h , mean day , and mean night heart rate ( HR ) did not differ significantly between placebo and lisinopril treatments . Repeated- measures analysis of variance ( ANOVA ) showed a significant influence on SBP ( p 0.001 ) and DBP ( p < 0.001 ) throughout the treatment . A significant time effect was also evident both for SBP ( p 0.001 ) and DBP ( p < 0.001 ) . The interaction of time and treatment was not significant , suggesting that the circadian rhythm of BP was not different during the two treatments . No serious side effects were observed during this study
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .